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A potential limitation in the use of biologic drugs used
to treat psoriasis is the development of anti-drug
antibodies (ADAs). Many factors contribute to this
unwanted immune response, from the product itself,
to its mode of administration, the underlying disease,
and patient characteristics. ADAs may decrease the
efficacy of biologic drugs by neutralizing them or
modifying their clearance and may account for hyper-
sensitivity reactions. This article reviews the scientific
basis of immunogenicity and the mechanisms by
which it affects clinical outcomes. It also considers
testing for immunogenicity and how biologic therapy
of psoriasis may be tailored on the basis of
immunogenicity.
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INTRODUCTION
Anti-drug antibodies (ADAs) are observed for all biologic
drugs used in the treatment of psoriasis; however, several
factors influence immunogenicity as not all patients appear to
develop ADAs, and the frequency varies from one drug to
another (Hsu et al., 2014). Loss of response due to immuno-
genicity has been shown to be associated with the presence of
ADAs for mAb tumor necrosis factor (TNF) inhibitors and
ustekinumab but not for the fusion protein etanercept (Hsu
et al., 2013). Therefore––and primarily due to the antigenic
structure they target on the therapeutic molecule––ADAs can
be considered a heterogeneous phenomenon with a distinct
clinical impact. ADAs may indirectly influence drug efficacy
by altering drug pharmacokinetics and pharmacodynamics,
and hence assessment of serum drug levels and immuno-
genicity is becoming a useful tool for tailored management of
biologic therapy in psoriasis. Key data on the immunogenicity
of TNF inhibitors used in psoriasis have been obtained in
rheumatoid arthritis (RA), ankylosing spondylitis, and inflam-
matory bowel disease, and, although they are presented here,
they may not translate directly to psoriasis patients.
FACTORS THAT ACCOUNT FOR AND INFLUENCE
IMMUNOGENICITY OF BIOLOGICS
The immune response against biologic agents occurs via a
helper T-cell–dependent humoral response, evidenced by the
fact that ADAs against adalimumab and infliximab are
predominantly high-affinity IgG isotypes, with a bias toward
IgG1 and IgG4 (Svenson et al., 2007; van Schouwenburg et al.,
2013). Immunogenicity of the targeted drug is influenced by
drug-related factors as well as patient factors and treatment
protocol.
Drug-related factors
One of the key determinants of immunogenicity is the primary
molecular structure of the drug and its posttranslational modi-
fications. In silico analysis aimed at predicting protein drug
immunogenicity is part of all biotherapy development pro-
grams. It may help detect HLA class II-binding epitopes and
allow engineering to eliminate immunogenic T helper-cell
epitopes or add tolerogenic ones (Parenky et al., 2014).
Nevertheless, ADAs can still be raised against several anti-
genic structures (Figure 1), including murine epitopes present
in chimeric and humanized mAbs or constructs, idiotopes and
allotopes present in all kind of mAbs and Fab constructs,
human neo-antigens present at the joining region of fusion
proteins, nonlinear epitopes present on aggregated drugs, and
nonhuman glycosylation.
Although fully human mAbs such as adalimumab and
ustekinumab have less immunogenic potential compared with
chimeric mAbs such as infliximab, they can still induce the
formation of human anti-human antibodies (Wolbink et al.,
2009). These ADAs are usually anti-idiotypic antibodies that
target the drug binding site, as this does not belong to the
immunoglobulin repertoire of the host. The humoral response
to adalimumab, for e.g., has been found in RA patients to be
highly restricted and limited to epitopes located in the TNF-
binding region; as a result, anti-adalimumab antibodies are
mostly neutralizing (i.e., they block the binding of the thera-
peutic agent to its target, TNF-a) (van Schouwenburg et al.,
2013). Patients not endowed with G1m(a) and G1m(x) may
generate ADAs against these allotopes present on infliximab;
however, there is no clear evidence that anti-allotype
antibodies are present in patients treated with adalimumab
or infliximab (Schellekens, 2002). For fusion proteins such as
etanercept, which combines a naturally occurring receptor to
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the Fc region of a fully human immunoglobulin, epitopes
recognized by the immune system as foreign may be present
in the joining region of the molecule (Wolbink et al., 2009).
An immunogenic epitope has been located in the fusion part
of the fusion protein lenercept (Christen et al., 1999), and this
is also likely to be the case for etanercept. The joining region
is not involved in drug binding; consequently, only non-
neutralizing ADAs against etanercept have been detected
(Emi Aikawa et al., 2010; Hsu et al., 2013). Among bio-
logics, bivalent mAbs––or constructs––are more likely to form
larger immune complexes with ADAs compared with fusion
proteins. Large immune complexes may favor immunogenicity
through B-cell activation due to extensive cross-linking,
enhanced uptake processing, and presentation of the drug
by antigen-presenting cells that favor helper T cells and
isotype switching toward high-affinity IgG-isotype ADAs.
The European Medicines Agency recognizes that a protein’s
immunogenic potential is influenced by product- and process-
related impurities, excipients, and stability of the product,
making immunogenicity a concern in the development of
biosimilar products (European Medicines Agency 2006). A
small change in the manufacturing process can affect glycosy-
lation, which may have an impact on immunogenicity.
Conserved mammalian sugars usually diminish immuno-
genicity through reduced product aggregation and shielding
of immunogenic epitopes from the immune system, whereas
foreign glycoforms trigger it. For mAbs, investigation of
immunogenicity is especially important when a different
expression system is employed for the biosimilar mAb com-
pared with the reference product (European Medicines Agency
2012). In a Phase I randomized study, which compared the
infliximab biosimilar Remsima with the originator product
Remicade, ADAs were detected in 27% (n¼32) of ankylosing
spondylitis patients on Remsima and in 23% (n¼ 25) of those
on Remicade (Park et al., 2013).
Chemical modifications such as oxidation, deamidation,
aldehyde modification, and deimination, which can occur
during the manufacturing process and also in vivo, notably
in an inflammatory environment, may also favor immune
responses.
Immunogenicity of biologics can be reduced through
pegylation via epitope shielding (Harris et al., 2001). Recent
publications have suggested that anti-polyethylene glycol anti-
bodies can develop and have adverse clinical consequences,
although this issue is currently questioned (Schellekens et al.,
2013).
Patient-related factors
According to currently used assays, not all patients receiving
the same biologic under similar conditions will develop
ADAs. However, those who develop ADAs against a first
TNF inhibitor are more likely to develop ADAs against a
second agent (Bartelds et al., 2010; Chirmule et al., 2012),
possibly due to genetic susceptibility. For e.g.,, particular HLA
alleles have been linked to the production of antibodies
against insulin (Schellekens, 2002). Possible associations
between IL-10 genotype and ADA development against
adalimumab have also been described (Astermark, 2012).
The patient’s underlying disease is another important factor.
Higher baseline disease activity was reported in RA patients
who developed ADAs, suggesting a role of inflammation in






















Strong effect on immunogenicity
Weak effect on immunogenicity
1. Murine epitope: Murine complementarity-derived regions±framework regions of Fab
2. Idiotope: Molecular structure in the variable region of Fab that confers antigenic specificity. Idiotopes may be allocated at the
     antigen-binding site or on variable region sequences outside of it
4. Human neo-antigens: Joining region of fusion proteins
Humanized
-xumab
3. Allotope: Genetic variants within the constant region sequences of particular isotypes (k, IgG1-chains),
    i.e., patients not endowed with a given allotype may generate ADAs against this allotope if it is present on the drug
5. Polyethylene glycol (PEG) moiety: Clinical relevance of anti-PEG antibodies is debated
Figure 1. Molecular structures of biologic drugs used to treat psoriasis. Neutralizing anti-drug antibodies (ADAs) bind to murine epitopes and idiotopes located at
the antigen-binding site and prevent fixation of the therapeutic agent to its target, reducing its clinical efficacy. In contrast, ADAs that bind to allotopes and human
neo-antigens at the hinge of fusion proteins are usually non-neutralizing. Both neutralizing and non-neutralizing ADAs may reduce drug efficacy through the
formation of immune complexes, which may lead to increased drug clearance.
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Bartelds et al., 2011). Patients with infections that may trigger
natural immunity and therefore enhance immune response
may also be more prone to developing ADAs (European
Medicines Agency 2007). Although infections are not
common in psoriasis, recent genome-wide association
studies (Tsoi et al., 2012) point to genetically determined
overactivation of innate immunity as one of the key elements
involved in the disease.
Treatment-related factors
Factors that may influence the risk of sensitization include the
drug dose (and serum concentration), administration route,
frequency of administration, and duration of treatment. A lower
dose administered intermittently is typically more immuno-
genic compared with a larger dose administered without
interruption (European Medicines Agency 2007); Food and
Drug Administration 2013; Parenky et al., 2014). Intravenous
administration is generally considered less immunogenic than
the intradermal or subcutaneous routes that are commonly
used in vaccination because they favor antigen-presenting cell
uptake and presentation. However, increased immunogenicity
linked to subcutaneous administration is not automatic, as
subcutaneous tocilizumab is not more immunogenic compared
with intravenous tocilizumab in the treatment of RA
(Burmester et al., 2014).
In psoriasis patients, both EXPRESS II and SPIRIT studies
found higher rates of ADA development in those treated with
infliximab at 3 mg kg1 versus 5 mg kg 1; similarly, in the
PHOENIX 1 and 2 studies, patients receiving 45 mg ustekinu-
mab were more likely to develop ADAs compared with those
on the 90-mg dose, with a greater difference in patients over
100 kg (Jullien, 2012). It was proposed that the use of high-
dose infliximab may reduce immunogenicity and induce
tolerance through exhaustion of the immune response (Maini
et al., 1998).
In psoriasis and RA patients treated with adalimumab, ADAs
usually develop during the first 6 months of treatment (Bartelds
et al., 2011; Menting et al., 2014). Transient ADAs were
reported in psoriasis for a small proportion of patients treated
with adalimumab (Menting et al., 2014) and a higher
proportion of patients treated with high doses of etanercept
(Tyring et al., 2007). ADAs decline over time in some patients,
suggesting induction of immune tolerance (Krieckaert et al.,
2012a; van Schouwenburg et al., 2013). Desensitization
protocols have been proposed in patients with injection-site
reactions to etanercept and adalimumab or systemic reactions
to infliximab (Hong et al., 2012). Sustained tolerization
requires continuous exposure to the medication. Accordingly,
the European Medicines Agency underlines that long term
rather than short term and continuous rather than intermittent
treatment appears to decrease the risk of immunogenicity
(European Medicines Agency 2007).
In psoriasis patients in EXPRESS II, intermittent infliximab
was associated with higher rates of ADA development com-
pared with continuous treatment (Jullien, 2012). However, in
PHOENIX 1, only 4.4% of psoriasis patients developed ADAs
after ustekinumab treatment was stopped and restarted
(Jullien, 2012).
Typically, the immune reaction against a therapeutic protein
is reduced when immunosuppressive agents such as metho-
trexate (MTX)––which kills antigen-activated lymphocytes
and/or elicits activity of regulatory T cells––are used conco-
mitantly (Baert et al., 2003; European Medicines Agency
2007; Food and Drug Administration 2013; Parenky et al.,
2014). A meta-analysis conducted in 936 patients (40%
RA and 47% inflammatory bowel disease) treated with
adalimumab or infliximab showed that concomitant MTX or
azathioprine/mercaptopurine reduced detectable ADA frequency
by about 47% (64% for ADAs assessed by radioimmunoassay)
(Garceˆs et al., 2013). In contrast, one study in psoriasis
patients treated with adalimumab found that MTX did not
reduce the development of ADAs (Menting et al., 2014).
However, cautious interpretation of these results is needed as
only eight patients received concomitant MTX, out of whom
three developed low titers of ADAs. In RA, concomitant MTX
reduces the immunogenicity of adalimumab in a dose-
dependent manner (Krieckaert et al., 2012b). The level of
evidence varies among inflammatory diseases, and available
data do not recommend concomitant use of MTX in psoriasis
just to avoid immunogenicity, but a preventive role of
immunosuppressive drugs on ADA development across this
group of diseases remains a prevalent hypothesis (Hsu et al.,
2014; Jani et al., 2014; Menting et al., 2014). The mechanism
involved is unclear, but findings from murine models of
noninflammatory disease suggest that MTX reduces T-
and B-cell expansion when administered shortly after an
immunogenic therapeutic enzyme (Garman et al., 2004;
Joseph et al., 2008). The ability to return immunized
patients to a negative ADA status has also been suggested
but with a weaker level of evidence to support it in psoriasis
(Adis¸en et al., 2010) and inflammatory bowel disease patients
(Ben-Horin et al., 2013). Reduced disease activity could allow
for higher available blood concentration of the drug, which
may favor tolerization. However, the curative effect is not
supported by murine models (Garman et al., 2004; Joseph
et al., 2008), and the idea that higher available drug conce-
ntration may only impair the ability to detect ADAs cannot be
excluded.
ADAS AND HOW THEY INFLUENCE CLINICAL
OUTCOMES
Neutralizing ADAs have been shown to develop in response
to ustekinumab, infliximab, and adalimumab (Zhu et al.,
2010; Bartelds et al., 2011; Ducourau et al., 2011; Plasencia
et al., 2012; Hsu et al., 2014). These ADAs may reduce
therapeutic activity by binding to the drug binding site and by
increasing drug clearance due to the formation of immune
complexes (Anderson, 2005; Wolbink et al., 2009) (Figure 1).
In psoriasis patients, ADAs to ustekinumab increased apparent
drug clearance by 35% (Zhu et al., 2010), and ADAs to
adalimumab are associated with lower serum and trough
concentration (Takahashi et al., 2013; Menting et al., 2014;
Hsu et al., 2014). The presence of ADAs does not preclude a
clinical response as long as they do not bring the concen-
tration of the unbound active drug below the therapeutic level
(van Schouwenburg et al., 2013).
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Non-neutralizing ADAs bind to epitopes outside of the drug
binding site and thus do not inhibit clinical activity. Only non-
neutralizing ADAs have been detected for etanercept, and
they are not associated with loss of efficacy (Vincent et al.,
2013; Hsu et al., 2014). This suggests that increased drug
clearance due to immune complex formation, which might
occur with these ADAs, is not significantly involved in
etanercept. Immune complexes can be either small (dimers
of one drug molecule and one antibody) or large (tetramers);
the latter are rapidly cleared from the circulation, whereas the
former appear to persist longer (Rojas et al., 2005; van der
Laken et al., 2007; van Schouwenburg et al., 2013). Different
patients may produce different sized complexes, with the
potential for varied pharmacokinetic outcomes. Immune
complexes may also have implications for safety. Non-
neutralizing antibodies may be responsible for injection-site
reactions, and successful etanercept desensitization in patients
with severe injection-site reactions has been reported (Bavbek
et al., 2011; Hall and Findeisen 2013). Theoretically, non-
neutralizing antibodies could also potentially prolong the drug
half-life or stimulate a pathway or mechanism (European
Medicines Agency 2007), although these issues have never
been addressed in psoriasis.
TESTING FOR IMMUNOGENICITY AND BIOLOGIC
DRUG LEVELS
No single assay is able to detect the different forms and
isotypes of ADAs, and assays differ in specificity and sensitiv-
ity. ELISAs and radioimmunoassays (e.g., antigen-binding tests)
detect mainly free ADAs but do not detect those that have
formed immune complexes with the drug (Hart et al., 2011).
Solid-phase ELISA is very sensitive but not very specific, often
resulting in false positives (Radstake et al., 2009). The two-site
bridging assay is both sensitive and specific but is highly
susceptible to drug interference and does not detect IgG4
antibodies (Wolbink et al., 2009). In the immune response
against adalimumab in RA patients, a considerable part of the
ADAs is IgG4 (van Schouwenburg et al., 2012). Most of what
we know about immunogenicity is based on assays that only
detect ADAs if the production of ADAs exceeds the amount of
drug present in patient serum, ignore ADAs bound to the drug
within an immune complex, and do not evaluate ADA affinity.
Because of these limitations, studies may have underestimated
the number of patients producing ADAs and overestimated the
causative role of ADAs in patients with low trough drug
concentration. The pH-shift anti-idiotype antigen-binding test
overcomes drug interference to detect ADAs in complexes
by using acid treatment to dissociate the complexes (van
Schouwenburg et al., 2010). Although used in a limited
number of studies, it has revealed ‘‘hidden’’ immunogenicity
and chronic exposure to immune complexes in virtually all RA
patients treated with adalimumab (van Schouwenburg et al.,
2010; van Schouwenburg et al., 2013). This observation raises
the compelling possibility that an immunogenic reaction
against biotherapies may develop in all patients. In patients
receiving negative ADA results with standard assays, some
may actually have low levels of ‘‘hidden’’ ADAs with limited
effect on drug level and clinical response, whereas others are
truly negative, having developed tolerance to the drug. Cell-
based assays are recommended by regulatory authorities but
are susceptible to serum matrix effects and not available for
routine use. Whichever assay method is selected, consistency
in the timing of sampling and the test methods used is
important. Direct comparison of immunogenicity between
biologics is hampered by the lack of standardized assays
and by drug interference. Drug interference may vary accord-
ing to the valency of the antibody-derived biologic; for e.g.,
IgG4 mAbs that become effectively monovalent in vivo due to
Fab arm exchange, and pegylated Fab fragments-like certoli-
zumab pegol, have less pronounced drug interference
compared with other bivalent therapeutic mAbs in antigen-
binding tests (Rispens et al., 2013).
Routine drug level monitoring and ADA measurements may
help optimize biologic treatment (Jamnitski et al., 2011; Garceˆs
et al., 2013). However, ADAs are a heterogeneous population
according to affinity, isotype, and neutralizing ability. ADAs
may develop early while clinical efficacy is still present, be
present at low levels, exist only within immune complexes, or
be transient. Optimal integration of ADA testing into daily
management will require an understanding of the clinical
relevance of these subsets and the development of standar-
dized, robust, and sensitive ADA assays for each drug that
allow reliable data interpretation and comparisons between
laboratories. To date, drug level testing for the amount of
available drug (i.e., drug not complexed to ADAs) remains the
best predictor of clinical response and may allow drug dose
optimization; this has been shown to be a valid approach for
biologic drugs used in treating Crohn’s disease (Cassinotti and
Travis, 2009) and RA (Chen et al., 2014).
CLINICAL IMPACT OF IMMUNOGENICITY
The consequences of immune responses to biologics range
from mild transient antibody responses––with no apparent
clinical manifestations––to loss of clinical response and life-
threatening reactions (European Medicines Agency 2007;
Food and Drug Administration 2013; Parenky et al., 2014).
Strong evidence exists in several diseases, and data in psoriasis
are now emerging, with psoriasis treatment guidelines also
recognizing immunogenicity as a consideration (Nast et al.,
2012).
Efficacy
Immunogenicity appears to be more important in terms of loss
of response to biologic drugs than for primary lack of efficacy.
In a group of 45 psoriasis patients who had been well
controlled on a TNF inhibitor for more than 18 months,
functional trough drug levels were detected in all patients and
none had detectable ADAs (Meyer et al., 2012). Clinical
response of psoriasis patients has been shown to be reduced in
patients with ADAs to infliximab (Reich et al., 2005; Menter
et al., 2007), adalimumab (Menter et al., 2008; Lecluse et al.,
2010; Menting et al., 2014), and ustekinumab (Zhu et al.,
2010). In studies of psoriasis patients treated with adalimumab
or infliximab, trough drug levels were positively associated
with clinical response and were significantly lower in patients
with ADAs (Takahashi et al., 2013; Menting et al., 2014).
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ADAs may reduce the likelihood of regaining a good
clinical response in patients resuming treatment after discon-
tinuation. The presence of ADAs to adalimumab was asso-
ciated with the failure to re-achieve efficacy following
discontinuation, particularly among psoriasis patients who
relapsed, although some ADA-positive patients did regain a
response (Papp et al., 2011). There is also indirect evidence of
this with infliximab; patients treated intermittently had higher
titers of ADAs, and the response rate at week 50 was lower in
patients who were responders and had ADAs at week 10
compared with those with no ADAs (Menter et al., 2007). In
contrast, a high proportion of etanercept-treated patients are
able to regain a similar response following discontinuation
and retreatment (Gordon et al., 2006; Ortonne et al., 2008).
Safety
Patients who develop ADAs are more likely to show anaphy-
lactic infusion reactions, which include cytokine release
syndrome and non-acute immune reactions such as immune
complex disease (European Medicines Agency 2007; Food
and Drug Administration 2013; Parenky et al., 2014).
Increased rates of infusion reactions have been reported in
patients with ADAs to infliximab (Gottlieb et al., 2004; Menter
et al., 2007), and injection-site reactions have been reported
for etanercept and adalimumab (Bavbek et al., 2011; Enbrel
(etanercept), Pfizer Inc 2013; Humira (adalimumab), AbbVie
2013). Emerging evidence suggests that thromboembolic
events are more common in patients with ADAs. Among
272 adalimumab-treated RA patients, those with ADAs had a
significantly greater risk of venous and arterial thromboem-
bolic events (adjusted hazard ratio 7.6, 95% CI 1.3–45.1;
P¼0.025) (Korswagen et al., 2011). Immune complexes could
contribute to the occurrence of thromboembolic events, but
other factors are likely to be involved as a vast majority of RA
patients treated with adalimumab are chronically exposed to
small immune complexes (van Schouwenburg et al., 2010;
van Schouwenburg et al., 2013).
Drug survival
Immunogenicity has an impact on drug survival, as seen in the
study of well-controlled psoriasis patients (Meyer et al., 2012).
Infliximab-treated patients without ADAs are more likely to
sustain their response to treatment (Menter et al., 2007). In RA
patients, early formation of anti-infliximab antibodies was
associated with subsequent discontinuation and dose increases
(necessitated by an inadequate clinical response) (Bendtzen
et al., 2006). A review of biologic drug survival in psoriasis
clinical trials found that etanercept had the highest retention
rates (Noiles and Vender, 2009). There is evidence that the
high rate of infliximab survival seen in the Danish DERMBIO
registry can be attributed to dose escalation, which may be an
attempt to overcome loss of efficacy linked to drug neutra-
lization but is associated with increased costs (Gniadecki
et al., 2011; Mehren and Gniadecki, 2012). The OSCAR study
of 650 psoriasis patients treated with a first TNF inhibitor
found significantly longer drug survival with etanercept com-
pared with infliximab and adalimumab (Esposito et al., 2013),
and it is possible that immunogenicity may be a combining
factor in this. In RA, immunogenicity has been shown to
determine patient response to a second TNF inhibitor, with
patients switching to etanercept after developing ADAs to
adalimumab or infliximab responding better compared with
switchers without ADAs (Jamnitski et al., 2011).
TAILORING BIOLOGIC THERAPY IN PSORIASIS ON THE
BASIS OF IMMUNOGENICITY
Drug-free remission is a desirable goal of psoriasis treatment
(Thalayasingham and Isaacs, 2011), and long-term episodes of
remission have been shown to be possible in some patients
(Koo and Lebwohl 1999; Cantini et al., 2008). In individual
patients, remission may be demonstrated by stopping
treatment or prolonging dosing intervals; flexibility of dosing
is preferred in such a situation. As intermittent treatment
may lead to development of ADAs in some patients,
biologics that do not induce ADAs (such as etanercept) may
be preferred for this strategy. Drug level and ADA testing may
help optimize biologic treatment and could be integrated into
daily management in the near future (Jamnitski et al., 2011).
Nonresponse to a TNF inhibitor in the absence of ADAs may
suggest a target-related reason for drug failure, and such
patients may thus be better suited to a drug with a different
mechanism of action (Vincent et al., 2013). In RA patients
receiving TNF inhibitors, therapeutic decisions made
accordingly via a decision tree that incorporates immuno-
genicity assessment perform better compared with ‘‘empirical-
switches’’ to improve outcomes (Garceˆs et al., 2013). Similar
algorithms still have to be transposed and tested prospectively
in psoriasis.
DEVELOPMENT AND FUTURE CHALLENGES
Efforts aimed at reducing the health and economic toll of ADA
formation will focus on prediction, prevention, assessment,
and cure. Before we can propose accurate prediction of
immunogenicity using preclinical models, we need to develop
a better insight into the interplay of the various immune
mechanisms involved in ADA development (Brinks et al.,
2013). Whether these mechanisms are shared for all biologic
agents or are drug specific will significantly impact the like-
lihood of bringing new drugs––engineered for minimal
immunogenicity––into clinical trials. Consequently, and
because immunogenicity is not only drug related, clinical
testing will remain critical in determining actual immuno-
genicity in patients. New assays that allow the detection of
ADAs within immune complexes and which are not drug
sensitive will be needed to understand how immunogenicity
actually develops. New assays will also help understand the
clinical consequences beyond treatment failure and help
determine whether early evaluation and monitoring of ADAs
can improve clinical outcomes. Pharmacogenetic (Yanover
et al., 2011; Astermark, 2012) or surrogate markers such as
previous ADA development (Bartelds et al., 2010; Chirmule
et al., 2012), preexisting anti-nuclear antibodies) (Pink et al.,
2010; Hoffman et al., 2011), anti-nuclear antibodies develop-
ment in patients receiving TNF inhibitors, or preexisting ADAs
in treatment-naı¨ve subjects (Xue and Rup, 2013) may all prove
to be useful in pinpointing at-risk populations or individuals.
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These patients could be offered drugs designed to have low
immunogenicity (i.e., with modified T-cell epitopes that do
not bind to specific MHC class II alleles) (Yanover et al., 2011)
or may be candidates for treatment strategies tailored to
increase tolerance (Scott, 2014). They may notably benefit
by co-prescription of immunosuppressants such as MTX
(Joseph et al., 2012; Krieckaert et al., 2012b; Dervieux
et al., 2013). Desensitization is today limited to patients
who developed clinically relevant side effects and cannot be
switched to other drugs. Because transient ADAs observed in
some patients suggest that tolerance can develop at any time,
ADA monitoring may also help indicate patients who would
benefit from a treatment adjustment in order to induce
tolerance in patients who develop this unwanted immune
response.
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